Nucleoside Metabolic Inhibitor [EPC]

209817 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE AZACITIDINE CAPECITABINE CYTARABINE CLOFARABINE NELARABINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE PENTOSTATIN

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 19156
1 DEATH 15493
2 NAUSEA 14065
3 NEUTROPENIA 11347
4 FEBRILE NEUTROPENIA 11320
5 VOMITING 11023
6 DISEASE PROGRESSION 10489
7 FATIGUE 10141
8 PYREXIA 9923
9 THROMBOCYTOPENIA 8510
See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY 147 0.8647
1 ACUTE MYELOID LEUKAEMIA RECURRENT 523 0.4373
2 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 168 0.4138
3 CAECITIS 166 0.3689
4 MYELODYSPLASTIC SYNDROME TRANSFORMATION 178 0.3633
5 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 6314 0.3623
6 NEUTROPENIC COLITIS 414 0.3301
7 TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA 131 0.3134
8 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 328 0.3121
9 MYCOBACTERIUM CHELONAE INFECTION 156 0.3120
See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]